Open an account

PharmaCyte Biotech

PMCB · NASDAQ

$0.3422+$0.0002 (+0.06%)TodayMarket closed ·
Prev close $0.342

About PMCB

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

Employees
2
Headquarters
Las Vegas, Nevada
Listed
Sep 11, 2003
Sector
Health Care
Industry
Biotechnology
Website
pharmacyte.com

PMCB key statistics

Market cap
3.67M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
130.19K
Volume
25.04K
Open price
$0.349
High today
$0.3703
Low today
$0.3401
52 Week high
$1.51
52 Week low
$0.3339

PharmaCyte Biotech (PMCB) at a glance

As of Oct 20, 2026, PharmaCyte Biotech (PMCB) shares are priced at $0.3422, giving the company a market cap of 3.67M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.3401 and $0.3703. The current price is 0.6% above the day's low and 7.6% below its high.

Volume so far is 25.04K shares, below the average of 130.19K shares a day.

Over the past year PharmaCyte Biotech has ranged from $0.3339 to $1.51, and now sits 1% of the way up that range.

PharmaCyte Biotech met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q1 FY27 it reported -$0.54 per share against an estimate of $0.00.

PMCB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 10.8% on average.

  1. Q3 FY22: reported -$0.04 per share against an estimate of -$0.051
  2. Q4 FY22: reported -$0.07 per share against an estimate of -$0.0408
  3. Q1 FY23: reported -$0.074 per share against an estimate of -$0.0714
  4. Q1 FY25: reported $0.14 per share against an estimate of $0.00
  5. Q2 FY25: reported -$0.29 per share against an estimate of $0.00
  6. Q3 FY25: reported -$0.10 per share against an estimate of $0.00
  7. Q1 FY26: reported -$0.09 per share against an estimate of $0.00
  8. Q1 FY27: reported -$0.54 per share against an estimate of $0.00

PMCB news

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releaseBusiness Wire

    PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

  • Press releaseBusiness Wire

    PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

  • Press releaseBusiness Wire

    PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releaseBusiness Wire

    PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

Similar companies

Companies in the same industry as PharmaCyte Biotech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.